Overview

* Cellectar Biosciences ( CLRB ) Q3 net loss narrows to $4.4 mln, with reduced R&D and G&A expenses

* Company plans to submit EMA application for iopofosine I 131 in 2026

* Received rare pediatric drug designation for iopofosine I 131 in r/r pHGG

Outlook

* Cellectar plans to submit a Conditional Marketing Approval application in Europe for iopofosine I 131 in 2026

* Company plans to submit a New Drug Application for iopofosine I 131 in the U.S. once funding is secured

* Cellectar is advancing a Phase 1b trial for CLR 125 in triple-negative breast cancer

Result Drivers

* R&D - xpenses were approximately $2.5 million, compared to approximately $5.5 million for the three months ended September 30, 2024. The overall decrease was primarily a result of reduced clinical trial costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$1.41

Q3 Net -$4.40

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Cellectar Biosciences Inc ( CLRB ) is $84.00, about 95.8% above its November 12 closing price of $3.50

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)